LUCD Quote, Financials, Valuation and Earnings

908 Devices, Inc. has a net margin of -858.55% compared to Lucid Diagnostics, Inc.'s net margin of -106.46%. Lucid Diagnostics, Inc.'s return on equity of -665.25% beat 908 Devices, Inc.'s return on equity of -41.37%.

Lucid Diagnostics, Inc. has a consensus price target of $3.79, signalling upside risk potential of 241.59%. On the other hand 908 Devices, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 83.49%. Given that Lucid Diagnostics, Inc. has higher upside potential than 908 Devices, Inc., analysts believe Lucid Diagnostics, Inc. is more attractive than 908 Devices, Inc..

Lucid Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison 908 Devices, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Lucid Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 908 Devices, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lucid Diagnostics, Inc. pays -- of its earnings as a dividend. 908 Devices, Inc. pays out -- of its earnings as a dividend.

Lucid Diagnostics, Inc. quarterly revenues are $1.2M, which are smaller than 908 Devices, Inc. quarterly revenues of $14M. Lucid Diagnostics, Inc.'s net income of -$10.4M is higher than 908 Devices, Inc.'s net income of -$14.9M. Notably, Lucid Diagnostics, Inc.'s price-to-earnings ratio is -- while 908 Devices, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lucid Diagnostics, Inc. is 21.09x versus 3.36x for 908 Devices, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PAVmed, Inc. has a net margin of -858.55% compared to Lucid Diagnostics, Inc.'s net margin of -120220%. Lucid Diagnostics, Inc.'s return on equity of -665.25% beat PAVmed, Inc.'s return on equity of 8.75%.

Lucid Diagnostics, Inc. has a consensus price target of $3.79, signalling upside risk potential of 241.59%. On the other hand PAVmed, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 3204.35%. Given that PAVmed, Inc. has higher upside potential than Lucid Diagnostics, Inc., analysts believe PAVmed, Inc. is more attractive than Lucid Diagnostics, Inc..

Lucid Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PAVmed, Inc. has a beta of 1.095, suggesting its more volatile than the S&P 500 by 9.503%.

Lucid Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lucid Diagnostics, Inc. pays -- of its earnings as a dividend. PAVmed, Inc. pays out -- of its earnings as a dividend.

Lucid Diagnostics, Inc. quarterly revenues are $1.2M, which are larger than PAVmed, Inc. quarterly revenues of $5K. Lucid Diagnostics, Inc.'s net income of -$10.4M is lower than PAVmed, Inc.'s net income of -$6M. Notably, Lucid Diagnostics, Inc.'s price-to-earnings ratio is -- while PAVmed, Inc.'s PE ratio is 0.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lucid Diagnostics, Inc. is 21.09x versus 256.11x for PAVmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

RxSight, Inc. has a net margin of -858.55% compared to Lucid Diagnostics, Inc.'s net margin of -32.35%. Lucid Diagnostics, Inc.'s return on equity of -665.25% beat RxSight, Inc.'s return on equity of -12.84%.

Lucid Diagnostics, Inc. has a consensus price target of $3.79, signalling upside risk potential of 241.59%. On the other hand RxSight, Inc. has an analysts' consensus of $10.33 which suggests that it could fall by -9.83%. Given that Lucid Diagnostics, Inc. has higher upside potential than RxSight, Inc., analysts believe Lucid Diagnostics, Inc. is more attractive than RxSight, Inc..

Lucid Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RxSight, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Lucid Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lucid Diagnostics, Inc. pays -- of its earnings as a dividend. RxSight, Inc. pays out -- of its earnings as a dividend.

Lucid Diagnostics, Inc. quarterly revenues are $1.2M, which are smaller than RxSight, Inc. quarterly revenues of $30.3M. Lucid Diagnostics, Inc.'s net income of -$10.4M is lower than RxSight, Inc.'s net income of -$9.8M. Notably, Lucid Diagnostics, Inc.'s price-to-earnings ratio is -- while RxSight, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lucid Diagnostics, Inc. is 21.09x versus 3.28x for RxSight, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sensus Healthcare, Inc. has a net margin of -858.55% compared to Lucid Diagnostics, Inc.'s net margin of -13.7%. Lucid Diagnostics, Inc.'s return on equity of -665.25% beat Sensus Healthcare, Inc.'s return on equity of -5.65%.

Lucid Diagnostics, Inc. has a consensus price target of $3.79, signalling upside risk potential of 241.59%. On the other hand Sensus Healthcare, Inc. has an analysts' consensus of $7.33 which suggests that it could grow by 93.49%. Given that Lucid Diagnostics, Inc. has higher upside potential than Sensus Healthcare, Inc., analysts believe Lucid Diagnostics, Inc. is more attractive than Sensus Healthcare, Inc..

Lucid Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sensus Healthcare, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.559%.

Lucid Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sensus Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lucid Diagnostics, Inc. pays -- of its earnings as a dividend. Sensus Healthcare, Inc. pays out -- of its earnings as a dividend.

Lucid Diagnostics, Inc. quarterly revenues are $1.2M, which are smaller than Sensus Healthcare, Inc. quarterly revenues of $6.9M. Lucid Diagnostics, Inc.'s net income of -$10.4M is lower than Sensus Healthcare, Inc.'s net income of -$943K. Notably, Lucid Diagnostics, Inc.'s price-to-earnings ratio is -- while Sensus Healthcare, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lucid Diagnostics, Inc. is 21.09x versus 1.74x for Sensus Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.